Stable IL-10: A New Therapeutic that Promotes Tumor Immunity

In this issue of Cancer Cell, Mumm et al. demonstrate that pegylated IL-10 increases CD8+ T cell numbers, IFN-γ secretion, and cytotoxicity in established tumors, enhancing antigen presentation machinery and suppressing tumor growth. This approach may enhance T cell immune responses in cancers with reduced T cell infiltration.